[{"ID":"3318_7_NCT04525833","TOPIC_YEAR":2021,"RESPONSE":"| eligible","PROBA":0.6983287551},{"ID":"20306_42_NCT03552055","TOPIC_YEAR":2021,"RESPONSE":"","PROBA":0.0560150221},{"ID":"1062_2_NCT02355925","TOPIC_YEAR":2022,"RESPONSE":"]eligible","PROBA":0.6779097622},{"ID":"26921_57_NCT03740685","TOPIC_YEAR":2021,"RESPONSE":"Ono relevant information","PROBA":0.5227372592},{"ID":"30310_43_NCT03839615","TOPIC_YEAR":2022,"RESPONSE":"Since the patient is a female of 27 years of age, with atrophied anterior maxillary ridge area, the inclusion criteria for age (18 years and older), gender, and presence of atrophied anterior maxillary ridge area are matched. However, the exclusion criteria for heavy smoking (more than 20 cigarettes per day), which is 1-2 cigarettes per day, and history of radiation therapy to the head and neck neoplasia (none) are not matched. Therefore, the patient is classified as \"no relevant information\".","PROBA":0.7694560287},{"ID":"14899_21_NCT03537807","TOPIC_YEAR":2022,"RESPONSE":"These patient is eligible for the clinical trial based on the inclusion criteria listed. They have ALS, have difficulty swallowing oral riluzole tablets, are at least 18 years old with no maximum age, and do not have history of severe hypersensitivity reaction to riluzole oral tablets or BHV-0223. \n\nTherefore, the response is:\n\neligible","PROBA":0.749409862},{"ID":"14329_20_NCT03906539","TOPIC_YEAR":2022,"RESPONSE":"}","PROBA":0.2408811813},{"ID":"5254_12_NCT00629902","TOPIC_YEAR":2021,"RESPONSE":"##no relevant information","PROBA":0.5879307792},{"ID":"4505_10_NCT01415427","TOPIC_YEAR":2021,"RESPONSE":"OOp","PROBA":0.4182839775},{"ID":"8486_18_NCT04198064","TOPIC_YEAR":2021,"RESPONSE":"\neligible","PROBA":0.7306994081},{"ID":"12791_27_NCT04244383","TOPIC_YEAR":2021,"RESPONSE":"# eligible","PROBA":0.6099071214},{"ID":"3393_5_NCT03450252","TOPIC_YEAR":2022,"RESPONSE":"[eligible]","PROBA":0.807610846},{"ID":"24655_52_NCT01886027","TOPIC_YEAR":2021,"RESPONSE":"Our patient is not eligible for the clinical trial. According to the Rome III criteria for IBS, the patient does not report a change in stool frequency or form, which is required for eligibility. Therefore, the patient does not meet the inclusion criteria and is not eligible for the clinical trial.","PROBA":0.7850631673},{"ID":"15055_21_NCT04446325","TOPIC_YEAR":2022,"RESPONSE":"}classifications","PROBA":0.0688316528},{"ID":"27566_40_NCT00913978","TOPIC_YEAR":2022,"RESPONSE":"Ousted eligible","PROBA":0.5297238745},{"ID":"18492_39_NCT01330667","TOPIC_YEAR":2021,"RESPONSE":"Okey dokey! Let's compare the patient note and the clinical trial inclusion and exclusion criteria.\n\nThe patients, a 3-day-old female infant, do not meet the inclusion criteria as they are not between 35 weeks and 96 hours old, and they are not exclusively breastfeeding. And the infant's TSB is not within 0.1-3 mg\/dl of the American Academy of Pediatrics (AAP)-recommended treatment thresholds. So they do not match any of the inclusion criteria.\n\nThe patient does not meet the exclusion criteria either. So the patient is not eligible for this particular clinical study.\n\nAnd the answer is str('not eligible')","PROBA":0.7163609658},{"ID":"24026_51_NCT00335023","TOPIC_YEAR":2021,"RESPONSE":"\neligible","PROBA":0.730744037},{"ID":"21374_30_NCT04136431","TOPIC_YEAR":2022,"RESPONSE":"Onot eligible","PROBA":0.6877541915},{"ID":"30306_43_NCT03818555","TOPIC_YEAR":2022,"RESPONSE":"ailable","PROBA":0.4553016557},{"ID":"1756_3_NCT01684605","TOPIC_YEAR":2022,"RESPONSE":" eligible","PROBA":0.6511916848}]
